The European Medicines Agency is moving from London to Amsterdam after a vote on Monday 20 November
In response to this announcement, Professor Sir Robert Lechler PMedSci, President of the Academy of Medical Sciences, said:
“Congratulations to Amsterdam for their successful bid to host the European Medicines Agency (EMA). Now that we know the future destination of the Agency, it is crucial for the health and safety of patients in the UK and the EU 27 that the transition is considered and pragmatic. In addition, the UK must work to ensure this does not negatively impact its thriving life sciences sector, which is a key source of employment and revenue.
“The EMA must be relocated in a way which allows the vital functions of the agency to continue at highest capacity during this significant shift. March 2019 is fast approaching and a hurried relocation to meet this date could be to the detriment of pan-European health. Patient wellbeing throughout Europe must not be compromised during this move.
“It would be mutually beneficial to consider taking a staggered approach to the relocation of the agency, thereby protecting public health in the UK and EU by ensuring continued access to new treatments, devices and diagnostics and clinical trials for patients throughout Europe.”